1. Home
  2. GTY vs PHVS Comparison

GTY vs PHVS Comparison

Compare GTY & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GTY

Getty Realty Corporation

HOLD

Current Price

$36.09

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$34.81

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GTY
PHVS
Founded
1955
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.4B
IPO Year
1998
2020

Fundamental Metrics

Financial Performance
Metric
GTY
PHVS
Price
$36.09
$34.81
Analyst Decision
Buy
Buy
Analyst Count
5
11
Target Price
$32.60
$41.82
AVG Volume (30 Days)
533.0K
566.0K
Earning Date
04-22-2026
05-12-2026
Dividend Yield
5.92%
N/A
EPS Growth
8.00
N/A
EPS
0.43
N/A
Revenue
$221,727,000.00
N/A
Revenue This Year
$9.39
N/A
Revenue Next Year
$7.83
N/A
P/E Ratio
$83.93
N/A
Revenue Growth
9.02
N/A
52 Week Low
$25.39
$19.12
52 Week High
$36.12
$36.60

Technical Indicators

Market Signals
Indicator
GTY
PHVS
Relative Strength Index (RSI) 73.33 57.18
Support Level $32.41 $24.73
Resistance Level N/A $36.60
Average True Range (ATR) 0.58 1.64
MACD 0.18 -0.14
Stochastic Oscillator 87.54 54.17

Price Performance

Historical Comparison
GTY
PHVS

About GTY Getty Realty Corporation

Getty Realty Corp is a net lease real estate investment trust in the U.S.A, specializing in the acquisition, financing, and development of convenience, automotive, and other single-tenant retail real estate. The company's portfolio includes convenience stores, express tunnel car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, and collision), drive-thru quick service restaurants, and certain other freestanding retail properties. It generates maximum revenue in the form of rental income.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: